We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BIA Separations Introduces PrimaS Multi-mode Ligand Bioprocessing Technology
Product News

BIA Separations Introduces PrimaS Multi-mode Ligand Bioprocessing Technology

BIA Separations Introduces PrimaS Multi-mode Ligand Bioprocessing Technology
Product News

BIA Separations Introduces PrimaS Multi-mode Ligand Bioprocessing Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BIA Separations Introduces PrimaS Multi-mode Ligand Bioprocessing Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BIA Separations, a bio-chromatography development and manufacturing company, has announced the introduction of its novel PrimaS™ ligand technology. The proprietary multi-use platform facilitates high-resolution and high speed processing and addresses many underserved but critical separation problems in the context of fast emerging advanced therapy medicinal products (ATMPs). The first application of PrimaS technology being made available is for mRNA purification addressing a rapidly growing interest in mRNA-based therapies.

As part of BIA Separations‘ CIMmultus™ range, PrimaS is a key addition to the company‘s mRNA purification toolbox, including Oligo dT-18, C4-HLD and SDVB chemistries. The platform harnesses mRNA capturing and polishing strategies, including dsRNA impurity removal and mRNA sizing options. All technologies are easily scalable from lab to manufacturing, and are able to provide better product quality than traditional purification systems.

mRNA manufacturing involves several complex bioprocessing steps beginning with plasmid DNA production and its linearization, followed by in vitro transcription (IVT). Both operations include finely balanced enzymatic reactions, utilizing a number of key raw materials. For the standards required for clinical applications, ultra-pure mRNA is required, with critical contaminants eliminated, including dsRNA, template DNA and respective enzymes, in addition to potential impurities from raw materials such as chromatin-like structures and endotoxins.

Advertisement